One crucial real-world outcome of increased NGS was learning that KRAS G12C commonly co-occurs with other pathogenic variants upon its diagnosis, which differs from the other established NSCLC driver mutations (e.g., EGFR) [10]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.